Details for Patent: 4,439,423

Summary for Patent: 4,439,423

Title:	Chymopapain and method for its use
Abstract:	An improved method for treating an intervertebral spinal disc in a mammalian subject which disc exhibits an abnormal condition, characterized by a reduced risk of toxic effect to the subject is provided which comprises, injecting in said disc an amount of a pharmaceutically acceptable solution of a purified chymopapain essentially free of proteolytically inactive and/or toxic protein components, said purified chymopapain being used in an amount sufficient to selectively dissolve the nucleus pulposus of said disc. Pharmaceutical compositions are also provided for said method which include a purified proteolytically active lyophilized chymopapain, essentially free of proteolytically inactive and toxic components, and an activating amount of a pharmaceutically acceptable reducing agent.
Inventor(s):	Smith; William S. (Libertyville, IL)
Assignee:	Smith Laboratories, Inc. (Rosemont, IL)
Application Number:	06/263,197
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 4,439,423

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,439,423

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	229179
Australia	555487
Australia	8364182
Canada	1179263